

Spinal muscular atrophy – onasemnogene abeparvovec – authority application

Online PBS Authorities



You do not need to complete this form if you use the **Online PBS Authorities** system.

For more information and how to access the **Online PBS Authorities** system, go to servicesaustralia.gov.au/hppbsauthorities

When to use this form

Use this form to apply for PBS-subsidised onasemnogene abeparvovec for patients 9 months or under with spinal muscular atrophy (SMA) who are either:

- untreated with disease modifying therapies for this condition
- switching from a disease modifying therapy to onasemnogene abeparvovec for this condition.

Important information

Authority applications for onasemnogene abeparvovec can be made using the **Online PBS Authorities** system or in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Under no circumstances will phone approvals be granted for authority applications for onasemnogene abeparvovec.

Treatment must be prescribed by, or in consultation with, a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital.

Recognised hospitals in the management of SMA are Queensland Children's Hospital (Brisbane), Royal Children's Hospital Melbourne, Monash Children's Hospital (Melbourne), John Hunter Hospital (Newcastle), Sydney Children's Hospital Randwick, Children's Hospital at Westmead, Adelaide Women and Children's Hospital and Perth Children's Hospital.

Patients must be treated in a treatment centre that:

- is recognised in the management of SMA
- is accredited in the use of this gene technology by the relevant authority, **and**
- will source or has sourced this product from an accredited supplier.

Accredited treatment centres and suppliers are those organisations accredited by the Gene Technology Regulator under section 92 of the *Gene Technology Act 2000*. The following website provides a list of accredited organisations and may update without notice:

ogtr.gov.au/what-weve-approved/accredited-organisations

Where the term 'gene therapy' appears, it refers to onasemnogene abeparvovec, and the term 'disease modifying therapy' refers to nusinersen or risdiplam.

State the weight of the patient in kilograms and request the appropriate product pack presentation with respect to the mix of 5.5 mL and 8.3 mL vials.

For treatment occurring after treatment with at least one disease modifying therapy for this condition (that is, switching from nusinersen/risdiplam to onasemnogene abeparvovec), adhere to any product information or local treatment guidelines with respect to treatment-free ('wash out') periods prior to administering this benefit.

The information in this form is correct at the time of publishing and may be subject to change.

Section 100 arrangements

This item is available to a patient who is attending a:

- public participating hospital recognised in managing SMA, **or**
- public hospital recognised in managing SMA

and is a:

- day admitted patient
- non-admitted patient, **or**
- patient on discharge.

This item is not available as a PBS benefit for in-patients of a public hospital.

The hospital name and provider number must be included in this authority form.

Treatment specifics

Patients must be undergoing treatment with onasemnogene abeparvovec once **ONLY** in a lifetime.

For more information

Go to servicesaustralia.gov.au/healthprofessionals

14 Has the condition progressed to a point where invasive permanent assisted ventilation is required in the absence of a potentially reversible cause (that is, ventilation via tracheostomy for at least 16 hours per day)?

Yes

No

15 Has the patient had prior treatment with nusinersen and/or risdiplam for this condition?

Yes and PBS-subsidised treatment with the replaced disease modifying agent has ceased or will cease prior to initiating this gene therapy ▶ **Go to 19**

No

16 This condition has genetic confirmation of:

5q homozygous deletion of the survival motor neuron 1 (SMN1) gene

or

deletion of one copy of the SMN1 gene, in addition to a pathogenic/likely pathogenic variant in the remaining single copy of the SMN1 gene.

17 The patient has:

Symptomatic Type 1 SMA with an onset before 6 months of age and experienced at least one of the following:

failure to meet or regression in ability to perform age-appropriate motor milestones

proximal weakness

hypotonia

absence of deep tendon reflexes

failure to gain weight appropriate for age

any active chronic neurogenic changes

a compound muscle action potential below normative values for an age-matched child

and

Provide the patient's age (in months) at the onset of these signs/symptoms

months

or

pre-symptomatic SMA

and

has genetic confirmation that there are **1 to 2** copies of the SMN2 gene determined by quantitative polymerase chain reaction (qPCR) or multiple ligation dependent probe amplification (MLPA)

or

has genetic confirmation that there are **3** copies of the SMN2 gene determined by qPCR or MLPA.

18 Provide details of the genetic testing

Date of pathology report (DD MM YYYY)

Name of pathology provider

Unique identifying serial number/code that links the genetic test result to the patient

Checklist

19  The relevant attachments need to be provided with this form.

Details of the proposed prescription(s) stating the correct combination of 5.5 mL and 8.3 mL vials based on the patient's weight.

Privacy notice

20 Personal information is protected by law (including the *Privacy Act 1988*) and is collected by Services Australia for the purposes of assessing and processing this authority application.

Personal information may be used by Services Australia, or given to other parties where the individual has agreed to this, or where it is required or authorised by law (including for the purpose of research or conducting investigations).

More information about the way in which Services Australia manages personal information, including our privacy policy, can be found at servicessaustralia.gov.au/privacypolicy

Prescriber's declaration

You do not need to **sign** the declaration if you complete this form using Adobe Acrobat Reader and return this form through Health Professional Online Services (HPOS) at servicesaustralia.gov.au/hpos

21 I declare that:

- I am aware that this patient must meet the criteria listed in the current Schedule of Pharmaceutical Benefits to be eligible for this medicine.
- I have informed the patient that their personal information (including health information) will be disclosed to Services Australia for the purposes of assessing and processing this authority application.
- I have provided details of the proposed prescription(s) and the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction.
- the information I have provided in this form is complete and correct.

I understand that:


- giving false or misleading information is a serious offence.

I have read, understood and agree to the above.

Date (DD MM YYYY) (you **must** date this declaration)

--	--	--	--	--	--	--	--	--	--

Prescriber's signature (**only** required if returning by post)



Returning this form

Return this form, details of the proposed prescription(s) and any relevant attachments:

- **online** (no signature required), upload through HPOS at servicesaustralia.gov.au/hpos
or
- by post (signature required) to
Services Australia
Complex Drugs Programs
Reply Paid 9826
HOBART TAS 7001